CAS 200940-22-3: 2,3-Dihydro-5-methyl-N-[6-[(2-methyl-3-pyridinyl)oxy]-3-pyridinyl]-6-(trifluoromethyl)-1H-indole-1-carboxamide

SB 243213 is a compound that has been extensively studied for its effects on melanogenesis and pigmentation. It acts as an antagonist for the IL-1 receptor, specifically IL-1RA, and the 5-HT2C receptor in humans. This compound has potential applications in the diagnosis and treatment of conditions related to pigmentation disorders such as vitiligo and melasma. Additionally, SB 243213 has shown promising results in cancer research, particularly as an inhibitory factor for melanoma cells. It can also be used in the development of microcapsules for targeted drug delivery in diseases like diabetes. Although not a fluoroquinolone or steroidal compound itself, SB 243213 belongs to the class of research chemicals that have gained attention in various scientific fields.

SB 243213 is a cell-permeable, potent, and selective inhibitor of the Kv1.3 potassium channel that is used as a research tool in pharmacology and cell biology. SB 243213 is a peptide that binds to the receptor site on the Kv1.3 channel and blocks ion flow, thereby inhibiting this type of potassium channel. The binding affinity of SB 243213 to the Kv1.3 receptor site is greater than 10,000 times higher than its binding affinity for other ion channels such as the nicotinic acetylcholine receptors. This agent has been shown to be an activator of protein interactions in cells and has also been used as an antibody labeling reagent.

SB 243213

SB 243213 is a 5-HT2C receptor antagonist with anxiolytic and antidepressant activity used in schizophrenia and movement disorders.